Friday 16 October 2026
Morning Edition
ZOTPAPER

News without the noise

ZOTPAPER
US Politics

Trump administration moves to ease access to unregulated peptide drugs

HHS submits interim access policy to the White House, aiming to allow compounding pharmacies to produce popular but unproven peptides

By LineZotpaper
Published
Read Time2 min
The Department of Health and Human Services has submitted a plan to the White House that would allow specialty pharmacies to compound certain peptide drugs, a class of largely unregulated injections that have gained popularity among followers of Health Secretary Robert F. Kennedy Jr. and wellness influencers. The policy, filed Thursday with the Office of Management and Budget, is the latest sign the Trump administration is seeking to widen access to products that have not undergone full FDA approval.

Peptides are the building blocks of proteins that trigger hormones for growth, metabolism and healing. Drug companies have brought several to market as approved medications, including treatments for diabetes and weight loss. However, the peptides targeted by the new policy have not gone through the rigorous FDA approval process, and most data on them comes from animal studies. They have nonetheless become popular for uses such as building muscle, improving appearance and boosting energy \u2014 uses not authorized by the FDA.

Two people familiar with the plan told Reuters that the policy is intended to allow pharmacies to temporarily compound some of the most popular peptides, including BPC-157, which is promoted for muscle building and injury recovery. The people spoke on condition of anonymity to discuss confidential deliberations. The approach, known as enforcement discretion, would effectively assure pharmacies that they will not be targeted for producing certain peptides.

The FDA had previously placed BPC-157 and more than a dozen other injectable peptides on a list of substances deemed too risky for compounding, citing potential contamination, allergic reactions and tumor growth. Earlier this year, Kennedy directed the agency to reconsider a short list of chemicals promoted by wellness influencers and fitness celebrities. In July, an external panel of FDA advisers recommended dropping restrictions on six of seven peptides, a move that went against the scientific conclusion of the FDA's own staff scientists, who reiterated that none had been studied enough to establish safety and effectiveness.

§

Analysis

Why This Matters

  • The policy could dramatically expand access to unproven peptide injections that millions of Americans already obtain through gray-market channels such as online platforms and Chinese suppliers.
  • It represents a significant shift in FDA enforcement priorities, potentially weakening the agency's ability to regulate products that have not been tested for safety and efficacy.
  • The move aligns with the Make America Healthy Again (MAHA) movement, whose leading figures sell peptide injections and supplements, and could set a precedent for other unregulated wellness products.

Background

Peptides are short chains of amino acids that occur naturally in the body and can trigger various biological responses. While some peptide-based drugs have received FDA approval after extensive clinical trials, many others are sold as "research chemicals" or dietary supplements without regulatory oversight. Compounding pharmacies traditionally mix customized medications for patients who cannot use commercially available drugs, but federal law restricts them from making products that are essentially copies of unapproved drugs or that pose significant safety risks. The FDA has historically maintained a list of substances that cannot be compounded due to safety concerns, which includes many of the peptides now being reconsidered.

Key Perspectives

Supporters (MAHA movement, wellness influencers, some compounding pharmacies): Argue that consumers should have access to peptides that many already use safely, and that restricting compounding drives people to riskier unregulated sources, including products from overseas. They view the FDA's caution as excessive and influenced by pharmaceutical industry interests.

Opponents (FDA staff scientists, patient safety advocates, traditional drugmakers): Contend that insufficient evidence exists to establish the safety or effectiveness of these peptides, and that bypassing the approval process exposes patients to unknown risks, including contamination, allergic reactions, and potential long-term harm such as tumor growth.

External FDA Advisory Panel: In July, a majority of independent advisers recommended dropping restrictions on six of seven peptides, but their recommendation explicitly went against the scientific conclusion of FDA staff scientists, who noted the lack of adequate studies.

What to Watch

  • The White House Office of Management and Budget's review: OMB could approve the policy, request changes, or block it, and the outcome will signal how aggressively the administration is pursuing deregulation.
  • Whether the FDA formally adds these peptides to its list of drugs safe for compounding, which would require official rulemaking and public comment.
  • Congressional or legal challenges: If the policy is implemented, safety advocates or drug companies may sue, arguing the FDA exceeded its authority by allowing compounding of substances it previously deemed too risky.

Sources

Zotpaper

Written by software from the reporting listed above, scored by an automated standards desk, and published without a person reading it first. If something here is wrong, tell the editor and it will be put right.

How we workSubscribe